WO2006088956A3 - Methods of predicting therpeutic response in atopic dermatitis to il-31 antagonists - Google Patents

Methods of predicting therpeutic response in atopic dermatitis to il-31 antagonists Download PDF

Info

Publication number
WO2006088956A3
WO2006088956A3 PCT/US2006/005328 US2006005328W WO2006088956A3 WO 2006088956 A3 WO2006088956 A3 WO 2006088956A3 US 2006005328 W US2006005328 W US 2006005328W WO 2006088956 A3 WO2006088956 A3 WO 2006088956A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
predicting
atopic dermatitis
therpeutic
antagonists
Prior art date
Application number
PCT/US2006/005328
Other languages
French (fr)
Other versions
WO2006088956A2 (en
Inventor
Donald Y M Leung
Janine Billsborough
Jane A Gross
Original Assignee
Zymogenetics Inc
Nat Jewish Med & Res Center
Donald Y M Leung
Janine Billsborough
Jane A Gross
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc, Nat Jewish Med & Res Center, Donald Y M Leung, Janine Billsborough, Jane A Gross filed Critical Zymogenetics Inc
Priority to CA2595939A priority Critical patent/CA2595939C/en
Priority to AU2006214326A priority patent/AU2006214326B2/en
Priority to JP2007555370A priority patent/JP4927762B2/en
Priority to EP06735137.9A priority patent/EP1856539B1/en
Priority to MX2007009577A priority patent/MX2007009577A/en
Publication of WO2006088956A2 publication Critical patent/WO2006088956A2/en
Publication of WO2006088956A3 publication Critical patent/WO2006088956A3/en
Priority to IL184776A priority patent/IL184776A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

The present invention relates to methods of treating atopic dermatitis patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cells. The invention also includes methods of predicting a therapeutically responsive patient population.
PCT/US2006/005328 2005-02-14 2006-02-14 Methods of predicting therpeutic response in atopic dermatitis to il-31 antagonists WO2006088956A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA2595939A CA2595939C (en) 2005-02-14 2006-02-14 Methods of predicting therpeutic response in atopic dermatitis to il-31 antagonists
AU2006214326A AU2006214326B2 (en) 2005-02-14 2006-02-14 Methods of predicting therapeutic response in atopic dermatitis to IL-31 antagonists
JP2007555370A JP4927762B2 (en) 2005-02-14 2006-02-14 Method for predicting therapeutic response of atopic dermatitis to IL-31 antagonist
EP06735137.9A EP1856539B1 (en) 2005-02-14 2006-02-14 Methods of predicting therapeutic response in atopic dermatitis to il-31 antagonists
MX2007009577A MX2007009577A (en) 2005-02-14 2006-02-14 Methods of predicting therpeutic response in atopic dermatitis to il-31 antagonists.
IL184776A IL184776A (en) 2005-02-14 2007-07-23 Methods of predicting therapeutic response in atopic dermatitis to il-31 antagonists

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US65311405P 2005-02-14 2005-02-14
US60/653,114 2005-02-14
US71676205P 2005-09-13 2005-09-13
US60/716,762 2005-09-13
US74995205P 2005-12-13 2005-12-13
US60/749,952 2005-12-13

Publications (2)

Publication Number Publication Date
WO2006088956A2 WO2006088956A2 (en) 2006-08-24
WO2006088956A3 true WO2006088956A3 (en) 2007-01-18

Family

ID=36685803

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2006/005327 WO2006088955A2 (en) 2005-02-14 2006-02-14 Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
PCT/US2006/005328 WO2006088956A2 (en) 2005-02-14 2006-02-14 Methods of predicting therpeutic response in atopic dermatitis to il-31 antagonists

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2006/005327 WO2006088955A2 (en) 2005-02-14 2006-02-14 Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells

Country Status (8)

Country Link
US (11) US20060188500A1 (en)
EP (2) EP1856150A2 (en)
JP (2) JP2008530137A (en)
AU (2) AU2006214325B2 (en)
CA (2) CA2595877A1 (en)
IL (3) IL184734A (en)
MX (2) MX2007009471A (en)
WO (2) WO2006088955A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9005921B2 (en) 2007-12-07 2015-04-14 Zymogenetics, Inc. Polynucleotides encoding IL-31 monoclonal antibodies

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075314A1 (en) 1999-06-02 2000-12-14 Chugai Research Institute For Molecular Medicine, Inc. Novel hemopoietin receptor protein nr10
AU7445900A (en) 1999-09-27 2001-04-30 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
PL211833B1 (en) 2002-01-18 2012-06-29 Zymogenetics Inc Isolated polypeptide, fusion protein, isolated polynucleotide molecule, expression vector, cultured cell, a method for obtaining the polypeptide, a method for obtaining an antibody, an antibody, an antibody or a fragment thereof, the use of the antibody, a method for detecting the presence of a polypeptide, a method for inhibition the hematopoietic cells proliferation or differentiation, the use of a polypeptide, a method for spreading of hematopoietic cells, a method for detecting RNA presence, a method of killing cancer cells in vitro or in vivo, the use of a polypeptide, the use of a polypeptide, antagonist and a method for detecting infection in a patient
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
AU2006207945B2 (en) * 2005-01-28 2012-02-09 Zymogenetics, Inc. Homogeneous preparations of IL-31
AU2006214404B2 (en) 2005-02-14 2012-03-08 Bristol-Myers Squibb Company Methods of treating skin disorders using an IL-31RA antagonist
WO2006088955A2 (en) * 2005-02-14 2006-08-24 Zymogenetics, Inc. Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
AU2007254715B2 (en) 2005-05-06 2013-08-29 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using IL-31 antagonists
BRPI0611069A2 (en) 2005-05-06 2010-11-09 Zymogenetics Inc monoclonal antibody, humanized antibody, antibody fragment, use of an antagonist, and hybridoma
US20130216542A1 (en) 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
PL2047863T3 (en) 2006-06-08 2014-01-31 Chugai Pharmaceutical Co Ltd Preventive or remedy for inflammatory disease
US8466262B2 (en) 2006-09-01 2013-06-18 Zymogenetics, Inc. Variable region sequences of IL-31 monoclonal antibodies and methods of use
US7799323B2 (en) * 2007-01-10 2010-09-21 Zymogenetics, Inc. Methods of using IL-31 to treat airway hyper-responsiveness and asthma
EP2241332A4 (en) 2007-12-05 2011-01-26 Chugai Pharmaceutical Co Ltd Therapeutic agent for pruritus
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
JP5650871B1 (en) * 2013-06-28 2015-01-07 中外製薬株式会社 Methods for predicting response to treatment with IL-31 antagonists in patients with pruritus-related diseases
MA43918A (en) * 2015-04-14 2018-12-05 Chugai Pharmaceutical Co Ltd PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF ATOPIC DERMATITIS CONTAINING AN IL-31 ANTAGONIST AS ACTIVE SUBSTANCE
KR102641898B1 (en) 2015-04-14 2024-02-27 추가이 세이야쿠 가부시키가이샤 Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
US10060273B2 (en) 2015-04-15 2018-08-28 United Technologies Corporation System and method for manufacture of abrasive coating
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
JP2021515800A (en) 2018-03-16 2021-06-24 ゾエティス・サービシーズ・エルエルシー Peptide vaccine against interleukin-31
JP7449234B2 (en) 2018-03-16 2024-03-13 ゾエティス・サービシーズ・エルエルシー Interleukin 31 monoclonal antibody for veterinary use
WO2019229525A2 (en) * 2018-04-25 2019-12-05 Kiniksa Pharmaceuticals, Ltd. TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRβ ANTIBODY
CN117018202A (en) * 2019-07-08 2023-11-10 上海交通大学医学院附属瑞金医院 Novel use of chemokine receptor CCR6 inhibitors for preventing psoriasis recurrence
RU2707181C1 (en) * 2019-08-15 2019-11-25 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Method for prurigo severity prediction by blood tryptase concentration determination method
KR20220098046A (en) 2019-11-20 2022-07-08 추가이 세이야쿠 가부시키가이샤 Antibody-containing preparation
KR102392954B1 (en) * 2020-02-11 2022-05-02 연세대학교 산학협력단 Manufacturing method of Avatar Mouse as an Atopic Dermatitis Animal Model, and use thereof
AU2020466800A1 (en) 2020-09-01 2023-03-23 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing IL-31 antagonist as active ingredient

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215838A1 (en) * 2002-01-18 2003-11-20 Sprecher Cindy A. Cytokine receptor zcytor17 multimers

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792850A (en) * 1996-05-23 1998-08-11 Zymogenetics, Inc. Hematopoietic cytokine receptor
EP1426059A4 (en) 2001-09-14 2007-01-17 Ono Pharmaceutical Co Remedies for pruritus
PL211833B1 (en) 2002-01-18 2012-06-29 Zymogenetics Inc Isolated polypeptide, fusion protein, isolated polynucleotide molecule, expression vector, cultured cell, a method for obtaining the polypeptide, a method for obtaining an antibody, an antibody, an antibody or a fragment thereof, the use of the antibody, a method for detecting the presence of a polypeptide, a method for inhibition the hematopoietic cells proliferation or differentiation, the use of a polypeptide, a method for spreading of hematopoietic cells, a method for detecting RNA presence, a method of killing cancer cells in vitro or in vivo, the use of a polypeptide, the use of a polypeptide, antagonist and a method for detecting infection in a patient
JP2004219390A (en) * 2002-02-22 2004-08-05 Taisho Pharmaceut Co Ltd Method of evaluating medicine having antipruritic effect to atopic dermatitis
EP1477170A4 (en) 2002-02-22 2007-09-05 Taisho Pharmaceutical Co Ltd Antipruritics
JP2004107209A (en) * 2002-09-13 2004-04-08 Nippon Oruganon Kk Therapeutic agent for pruritus
JP4503942B2 (en) * 2003-06-11 2010-07-14 大正製薬株式会社 Antidiarrheal
RU2346996C2 (en) 2004-06-29 2009-02-20 ЮРОПИЭН НИКЕЛЬ ПиЭлСи Improved leaching of base metals
AU2006207945B2 (en) 2005-01-28 2012-02-09 Zymogenetics, Inc. Homogeneous preparations of IL-31
AU2006214404B2 (en) * 2005-02-14 2012-03-08 Bristol-Myers Squibb Company Methods of treating skin disorders using an IL-31RA antagonist
WO2006088955A2 (en) * 2005-02-14 2006-08-24 Zymogenetics, Inc. Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
AU2007254715B2 (en) * 2005-05-06 2013-08-29 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using IL-31 antagonists
BRPI0611069A2 (en) 2005-05-06 2010-11-09 Zymogenetics Inc monoclonal antibody, humanized antibody, antibody fragment, use of an antagonist, and hybridoma
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
WO2007037137A1 (en) * 2005-09-28 2007-04-05 Konica Minolta Opto, Inc. Injection molding machine
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
US8466262B2 (en) * 2006-09-01 2013-06-18 Zymogenetics, Inc. Variable region sequences of IL-31 monoclonal antibodies and methods of use
US7799323B2 (en) 2007-01-10 2010-09-21 Zymogenetics, Inc. Methods of using IL-31 to treat airway hyper-responsiveness and asthma
HUE036548T2 (en) * 2007-12-07 2018-08-28 Zymogenetics Inc Humanized antibody molecules specific for IL-31

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215838A1 (en) * 2002-01-18 2003-11-20 Sprecher Cindy A. Cytokine receptor zcytor17 multimers

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BILSBOROUGH ET AL: "IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, vol. 117, no. 2, 7 February 2006 (2006-02-07), pages 418 - 425, XP005275428, ISSN: 0091-6749 *
DILLON STACEY R ET AL: "Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice", NATURE IMMUNOLOGY, NATURE PUBLISHING GROUP,, GB, vol. 5, no. 7, 6 June 2004 (2004-06-06), pages 752 - 760, XP002353112, ISSN: 1529-2908 *
LEUNG DONALD Y M ET AL: "New insights into atopic dermatitis.", JOURNAL OF CLINICAL INVESTIGATION, vol. 113, no. 5, March 2004 (2004-03-01), pages 651 - 657, XP002392299, ISSN: 0021-9738 *
SONKOLY ET AL: "IL-31: A new link between T cells and pruritus in atopic skin inflammation", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, vol. 117, no. 2, February 2006 (2006-02-01), pages 411 - 417, XP005275427, ISSN: 0091-6749 *
TAKAOKA A ET AL: "Expression of IL-31 gene transcripts in NC/Nga mice with atopic dermatitis", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 516, no. 2, 31 May 2005 (2005-05-31), pages 180 - 181, XP004947475, ISSN: 0014-2999 *
TAKAOKA A ET AL: "Involvement of IL-31 on scratching behavior in NC/Nga mice with atopic-like dermatitis.", EXPERIMENTAL DERMATOLOGY. MAR 2006, vol. 15, no. 3, March 2006 (2006-03-01), pages 161 - 167, XP002401005, ISSN: 0906-6705 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9005921B2 (en) 2007-12-07 2015-04-14 Zymogenetics, Inc. Polynucleotides encoding IL-31 monoclonal antibodies
US9416184B2 (en) 2007-12-07 2016-08-16 Zymogenetics, Inc. Method of treating pruritus with IL-31 monoclonal antibodies

Also Published As

Publication number Publication date
AU2006214326A1 (en) 2006-08-24
US20170096484A1 (en) 2017-04-06
IL184776A (en) 2014-06-30
MX2007009577A (en) 2008-01-30
US20090280121A1 (en) 2009-11-12
JP2008530138A (en) 2008-08-07
AU2006214325B2 (en) 2012-04-05
CA2595939C (en) 2014-08-19
US20090092999A1 (en) 2009-04-09
IL184734A (en) 2012-04-30
US20130203070A1 (en) 2013-08-08
AU2006214326B2 (en) 2011-09-29
EP1856539B1 (en) 2015-10-21
US20190040125A1 (en) 2019-02-07
US8435745B2 (en) 2013-05-07
WO2006088956A2 (en) 2006-08-24
US20060188500A1 (en) 2006-08-24
CA2595939A1 (en) 2006-08-24
EP1856150A2 (en) 2007-11-21
IL184734A0 (en) 2007-12-03
EP1856539A2 (en) 2007-11-21
US20130177563A1 (en) 2013-07-11
AU2006214325A1 (en) 2006-08-24
IL219145A0 (en) 2012-06-28
WO2006088955A3 (en) 2006-11-16
JP2008530137A (en) 2008-08-07
WO2006088955A2 (en) 2006-08-24
US20060188499A1 (en) 2006-08-24
US8926957B2 (en) 2015-01-06
MX2007009471A (en) 2008-02-15
US20110212093A1 (en) 2011-09-01
US7723048B2 (en) 2010-05-25
US8388964B2 (en) 2013-03-05
JP4927762B2 (en) 2012-05-09
IL184776A0 (en) 2007-12-03
CA2595877A1 (en) 2006-08-24
US20160024201A1 (en) 2016-01-28
US20100266600A1 (en) 2010-10-21

Similar Documents

Publication Publication Date Title
WO2006088956A3 (en) Methods of predicting therpeutic response in atopic dermatitis to il-31 antagonists
JP2008530138A5 (en)
WO2006085984A3 (en) Immune cell biosensors and methods of using same
RS20050198A (en) Therapeutic human anti-il-1r1 monoclonal antibody
WO2006076025A3 (en) Immune cell biosensors and methods of using same
WO2006066078A3 (en) Fcϝriib-specific antibodies and methods of use thereof
MY144906A (en) Human antibodies against il13 and therapeutic uses
WO2006076651A3 (en) Treatment method
WO2006003388A8 (en) Compositions and methods for treating inflammatory disorders
WO2007001264A3 (en) Method of making recombinant human antibodies for use in biosensor technology
WO2004080413A3 (en) Uses and formulations for transdermal or transmucosal application of active agents
WO2007109056A3 (en) Use of gelsolin to diagnose and treat inflammatory diseases
WO2005082032A3 (en) Treatment of attention disorders
ATE452908T1 (en) IL-10 MUTANT
WO2006012641A3 (en) Methods for detecting and treating autoimmune disorders
WO2008047150A3 (en) Protein variants
MX2009010092A (en) Apoptotic anti- ige antibodies binding the membrane-bound ige.
TW200728466A (en) Antibody molecules having specificity for human IL-6
WO2004096154A3 (en) Methods for treating degenerative diseases/injuries
WO2009018122A3 (en) Methods and compositions for increasing alpha-iduronidase activity in the cns
WO2006013087A8 (en) Human monoclonal antibodies against human il-4
WO2012054584A3 (en) Peptides for modulating t-cell activity and uses thereof
WO2002066981A3 (en) Monitoring soluble endothelial protein c receptor levels in anticoagulant therapy
WO2005099755A3 (en) Methods of treating autoimmune and inflammatory diseases
WO2004108208A3 (en) Methods and apparatus for conversion of eukaryotic cells by application of electric and magnetic fields

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 184776

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2595939

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006214326

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/009577

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007555370

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006214326

Country of ref document: AU

Date of ref document: 20060214

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006735137

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 4011/CHENP/2007

Country of ref document: IN